Vapotherm Inc
F:VA21
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vapotherm Inc
Accrued Liabilities
Vapotherm Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vapotherm Inc
F:VA21
|
Accrued Liabilities
$9.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Accrued Liabilities
$1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Accrued Liabilities
$4.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accrued Liabilities
$7.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accrued Liabilities
$1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
Vapotherm Inc
Glance View
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.
See Also
What is Vapotherm Inc's Accrued Liabilities?
Accrued Liabilities
9.4m
USD
Based on the financial report for Dec 31, 2023, Vapotherm Inc's Accrued Liabilities amounts to 9.4m USD.
What is Vapotherm Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
10%
Over the last year, the Accrued Liabilities growth was -22%. The average annual Accrued Liabilities growth rates for Vapotherm Inc have been -36% over the past three years , 10% over the past five years .
